you+ Medical Aesthetics - Batavia
you+ Medical Aesthetics - Batavia · 106 West Wilson Street · Batavia, IL 60510
5.0· 19 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- GLP-1 medications named on site
- Medically supervised weight loss
About this practice
you+ Medical Aesthetics - Batavia is a physician-led med spa in Batavia, Illinois, that also has an Aurora office. Its website says it serves Kane and DuPage counties, lists hair restoration, skin resurfacing and body treatments such as Sculpt, and includes semaglutide and tirzepatide weight-loss programs in which a provider customizes each plan after a consultation. Ali Dacanay, MD, is the physician named on the site. Google shows a 5.0-star rating across 19 reviews since 2023, with 3 in the past year, and reviewers most often mention the providers' knowledge and a caring approach, with results close behind.
Services & access
| Advertises semaglutide today | Yes |
| Advertises tirzepatide today | Yes |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2026-01-30. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★5.0 across 19 Google reviews. Of the 16 reviews we analyzed, 16 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
What patients like
- Knowledgeable, professional providers5 reviews
- Feeling listened to5 reviews
- Weight-loss results4 reviews
Common complaints
No negative reviews among those we analyzed.
Most recent Google reviews
Anel A.★★★★★2026-01-30Dr D really takes her time to explain everything and answer any questions before choosing the procedure that fits best your skin. I’m so glad I had the consultation, clarified a lot of thing for myself. Thank you Dr D!
Julie A.★★★★★2025-09-30Absolutely love Dr. D!! She took her time to get to know me and my skin care goals. Gave me several options and I got great results from my treatment! Highly recommend!!
Katie C.★★★★★2025-09-21Dr D is wonderful - she takes the time to explain all options for treatment. Highly recommend, I’ve been very happy with my results.
Joy V.★★★★★2025-09-10It’s been a few days since my treatment but so far so good. Most important is that Dr. D is informative, very caring and invites communication throughout the process. She is an MD with years of practical knowledge and provides the level of trust I was looking for
Christine★★★★★2025-04-28What a great service and super fun time! Who would have thought of a Botox PARTY! Thank you to Dr D for her insight and information along with a positive treatment experience 😊. 5 stars from me!
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs